JYNT

The Joint's FY2025 'turnaround' is thinner than the headlines. Net income swung to +$2.91M (EPS $0.19, +150%), but the MD&A shows this is almost entirely discontinued operations (+$3.18M) tied to shedding company-owned clinics under the refranchising strategy. Continuing operations still posted an operating loss of -$913K and a net loss of -$268K for the full year. So the 47x P/E is being applied to earnings that the core business did not generate — the underlying franchise engine is roughly breakeven, and the true valuation is richer than it looks.

That said, the trajectory and the balance sheet are genuinely constructive. Quarterly data shows continuing-ops income inflecting positive in H2 (Q3 +$290K, Q4 +$937K) after two loss quarters, consistent with a leaner, royalty-driven model emerging as the last 80 leased clinics are refranchised. The balance sheet is clean: $23.6M cash, essentially no long-term debt ($100K), and the 3.05x liabilities/equity ratio is lease- and deferred-franchise-revenue driven, not leverage stress. Capital allocation is aggressive and shareholder-friendly — $11.3M of stock bought back in FY2025 against a $17.0M authorization, shrinking the count 7% on a tiny $127M cap, with activist Bandera Partners (~28%, board seat) aligned behind it.